clostridium butyricum

Clostridium butyricum is a live anaerobic spore-forming probiotic bacterium used as an orally administered microbial therapeutic intended to restore gut microbial balance and increase local production of short-chain fatty acids, especially butyrate. In the provided sources it appears as conventional probiotic drug products such as powders, capsules, and tablets, including products from Qingdao Eastsea Pharmaceutical, and is being studied across gastrointestinal, allergic, hepatic, perioperative, and oncology settings. Its proposed therapeutic activity is mediated through microbiome modulation, reinforcement of intestinal barrier and immune homeostasis, suppression of pro-inflammatory signaling, and butyrate-associated effects on host immunity; in published and trial contexts it has been evaluated for atopic dermatitis prevention or treatment, ulcerative colitis with food allergy, infantile diarrhea, bronchopulmonary dysplasia risk modulation, hepatic encephalopathy prevention after TIPS, and as an adjunct in several cancer settings. The exact pharmacology is product- and context-dependent because the active agent is the live microorganism rather than a single purified molecular target.

Brand names

A Taining

Other names

Clostridium butyricumClostridium butyricum capsulesClostridium butyricum tabletsClostridium butyricum live tabletsClostridium butyricum live bacteria capsulesClostridium butyricum powderClostridium butyricum live powderClostridium butyricum viable capsuleClostridium butyricum combined viable capsuleClostridium caseinate live powder